cjc-1295 ipamorelin vials + Vial 16mg — Stemcode Peptides CJC-1295 (no DAC) + Ipamorelin

Blood 2010;116:43384348

Use With Caution In Research Models Involving: Diabetes or impaired glucose regulation Insulin resistance or metabolic syndrome Cardiovascular disease or uncontrolled hypertension Fluid-retention susceptibility or fluid-balancerelated conditions Hormonal or endocrine disorders Sleep apnea or significant respiratory disorders Chronic migraines or neurological sensitivity Kidney or liver impairment Avoid or Carefully Evaluate in Research Models With: Active or suspected malignancies History of growth-sensitive tumors Severe uncontrolled endocrine disorders Severe uncontrolled cardiovascular disease Pregnancy or breastfeeding contexts Known hypersensitivity to peptide compounds Additional Research Considerations Because Ipamorelin may increase endogenous growth hormone and downstream IGF-1 activity, research involving abnormal cellular proliferation, tumor-growth pathways, or uncontrolled metabolic disease should be approached with particular caution

pmid:10692382 26

Chemosensitivity in CSC is enhanced by a rise in the expression of the ATP-binding cassette (ABC) transporter, which plays a role in expelling chemotherapy [304, 305]